Market reactionShares rose 12% on Nov 4.
Ascentage Pharma sells olverembatinib and lisaftoclax for blood cancers in China and is running global Phase 3 trials; neither drug is approved in the U.S.
Ascentage sells two blood-cancer drugs in China: olverembatinib, covered by national reimbursement, and lisaftoclax, a Bcl-2 inhibitor approved in July 2025 after BTK-inhibitor failure in CLL/SLL. First-half 2026 revenue was $44.5 million, up 29%. Ascentage plans to seek reimbursement for lisaftoclax in 2026 and runs global Phase 3 trials in CLL, AML, MDS and Ph+ ALL. It held $279.4 million at June 30 against about $305 million of bank loans, mostly due within a year.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Lisaftoclax wins reimbursement
Is lisaftoclax added to China's national reimbursement list?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Ascentage's China sales are growing; lisaftoclax awaits reimbursement and global Phase 3 data
First China-approved Bcl-2 inhibitor beyond AbbVie's venetoclax, racing four global Phase 3s on $279M of cash
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Blood cancers, Gastrointestinal cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
10 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.